Final CRWV Deadline Reminder: March 13, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP Accessibility Statement Skip NavigationDid you buy CRWV securities between March 28, 2025, and December 15, 2025?Affected CRWV Investor Summary- Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com for recovery options- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's ability to meet customer demand for its service- ...

Core Viewpoint - Boston Scientific Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its revenue outlook and market competition [1]. Company Overview - Boston Scientific develops, manufactures, and markets medical devices for various interventional medical specialties globally [1]. Class Action Details - The class action lawsuit, titled Troike v. Boston Scientific Corporation, includes investors who purchased Boston Scientific common stock between July 23, 2025, and February 3, 2026, with a deadline of May 4, 2026, to seek lead plaintiff status [1]. - Allegations include that Boston Scientific executives made false statements about the company's revenue projections and downplayed risks from market competition and macroeconomic factors [1]. Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, showing a GAAP net income of $672 million or $0.45 per share for Q4 2025, compared to $566 million or $0.38 per share a year prior [1]. - For the full year 2025, the company reported a GAAP net income of $2.898 billion or $1.94 per share, up from $1.853 billion or $1.25 per share the previous year, with adjusted EPS of $3.06 compared to $2.51 a year ago [1]. - The company's stock price fell over 17% following the announcement of these results, which did not meet the company's guidance range of $0.48 to $0.52 per share [1].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. for allegedly misleading investors regarding its sales growth during the specified period [1][3]. Group 1: Lawsuit Details - The lawsuit represents investors who acquired BellRing securities from November 19, 2024, to August 4, 2025 [1][2]. - Investors have until March 23, 2026, to seek appointment as lead plaintiff [2]. Group 2: Allegations Against BellRing - The complaint claims that BellRing's CEO and CFO misrepresented sales growth as being driven by increased consumer demand and organic growth, while downplaying competitive impacts [3]. - Contrary to these statements, the lawsuit alleges that sales were primarily driven by inventory stockpiling by key customers [4]. Group 3: Stock Price Impact - On May 6, 2025, following revelations about reduced inventory supply by retailers, BellRing's stock price fell by $14.88, or 19%, from $78.43 to $63.55 per share [5]. - On August 4, 2025, after adjusting its fiscal year 2025 sales outlook due to competition, the stock plummeted by $17.46, or 33%, from $53.64 to $36.18 per share [6].

Core Viewpoint - A securities fraud class action lawsuit has been filed against PayPal Holdings, Inc. for alleged material misstatements regarding the company's revenue outlook and growth expectations during the class period from February 25, 2025, to February 2, 2026 [1]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that PayPal made materially false and misleading statements and failed to disclose adverse facts about its business operations [1]. - Investors who purchased PayPal common stock during the specified class period can seek lead plaintiff status by April 20, 2026 [1]. Financial Impact - Following a surprise leadership change and a disappointing earnings report on February 3, 2026, PayPal's stock price dropped by $10.63, or 20.3%, closing at $41.70 per share [1]. Legal Actions and Options for Investors - Investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation and can choose to retain counsel or take no action [1]. - The lead plaintiff process allows investors to represent the class in litigation, with no cost to participate [1]. About Kessler Topaz Meltzer & Check, LLP - Kessler Topaz Meltzer & Check, LLP is a prominent law firm specializing in securities fraud class actions, having recovered over $25 billion for clients [1].

Core Points - Driven Brands Holdings Inc. is facing a securities fraud class action lawsuit due to erroneous financial statements that led to a 39% decline in stock price [1] - The lawsuit is based on allegations that the company and its executives failed to disclose material information during the class period from May 9, 2023, to February 24, 2026 [1] - The company disclosed on February 25, 2026, that it identified at least seven categories of material errors in its financial statements for fiscal years 2023 and 2024, necessitating a restatement [1] Legal Context - Investors who suffered substantial losses have until May 8, 2026, to file lead plaintiff applications in the class action lawsuit against Driven Brands [1] - The case is currently pending in the United States District Court for the Southern District of New York, under the title Clark v. Driven Brands Holdings Inc., et al. [1] - Kahn Swick & Foti, LLC is representing the investors and is recognized as a leading firm in securities litigation [1]

Core Viewpoint - A class action lawsuit has been filed against Nektar Therapeutics and certain officers for alleged violations of federal securities laws during the Class Period from February 26, 2025, to December 15, 2025 [1] Company Overview - Nektar Therapeutics is a biopharmaceutical company focused on developing therapies that modulate the immune system for treating autoimmune disorders [1] - The lead product candidate is rezpegaldesleukin (REZPEG or NKTR-358), aimed at treating alopecia areata [1] Clinical Trial Details - In March 2024, Nektar initiated the Phase 2b REZOLVE-AA trial to evaluate rezpegaldesleukin in 94 patients with severe-to-very severe alopecia areata [1] - The trial's enrollment criteria included specific diagnostic and treatment history requirements [1] - In February 2025, Nektar announced the completion of target enrollment for the REZOLVE-AA trial [1] Allegations in the Lawsuit - The Complaint alleges that during the Class Period, Nektar's executives made materially false and misleading statements regarding the company's business and compliance policies [1] - Specific allegations include failure to disclose that enrollment in the REZOLVE-AA trial did not follow applicable standards, which could negatively impact trial results [1] - The integrity and prospects of the REZOLVE-AA trial were allegedly overstated, leading to misleading public statements [1] Impact of Trial Results - On December 16, 2025, Nektar announced that the REZOLVE-AA trial failed to reach statistical significance, attributed to the inclusion of ineligible patients [1] - Following this announcement, Nektar's stock price fell by $4.14 per share, or 7.77%, closing at $49.16 per share [1]

Core Viewpoint - A class action lawsuit has been filed against NuScale Power Corporation, alleging securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by April 20, 2026 [1] Financial Performance - NuScale reported a significant increase in general and administrative expenses, which surged over 3,000% to $519 million in Q3 2025, compared to $17 million in the same period the previous year [1] - The company's quarterly net loss escalated to $532 million, up from $46 million in the prior year [1] Business Developments - The increase in expenses was primarily due to a $495 million payment to ENTRA1 Energy LLC related to an agreement to develop power plants for the Tennessee Valley Authority, which could involve up to six gigawatts of new nuclear power generation [1] - Analysts questioned NuScale's management about ENTRA1's capability to operate the energy generation facilities as per the TVA agreement, which could lead to milestone payments exceeding $3 billion [1] Market Reaction - Following the announcement of the financial results and the lawsuit, NuScale's stock price dropped by $7.57 per share, or 19.97%, closing at $30.34 per share on November 7, 2025 [1]

Core Viewpoint - Eos Energy Enterprises, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with significant financial losses reported by investors during the specified class period [1]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Yung v. Eos Energy Enterprises, Inc., and it allows investors who purchased Eos Energy securities between November 5, 2025, and February 26, 2026, to seek appointment as lead plaintiff by May 5, 2026 [1]. - Allegations against Eos Energy include failure to meet production and capacity utilization targets, excessive battery line downtime, delays in automated production quality, and inadequate systems for accurate public disclosures [1]. Group 2: Financial Performance - Eos Energy reported full year 2025 revenue of $114.2 million, significantly below the previously issued guidance of $150 million to $160 million [1]. - The company disclosed a gross loss of $143.8 million and a net loss attributable to shareholders of $969.6 million for the same period [1]. - An adjusted EBITDA loss of $219.1 million was also reported, along with a capacity milestone that was reached five weeks later than planned [1]. Group 3: Stock Market Reaction - Following the announcement of the disappointing financial results on February 26, 2026, Eos Energy's stock price fell by more than 39% [1]. Group 4: Legal Representation - Robbins Geller Rudman & Dowd LLP is leading the class action lawsuit and is recognized as a top law firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1].

Core Viewpoint - The monday.com class action lawsuit alleges that the company and its executives made misleading statements regarding its revenue outlook and growth potential, leading to significant investor losses during the specified class period [1]. Group 1: Class Action Details - The class action lawsuit seeks to represent purchasers of monday.com Ltd. common stock from September 17, 2025, to February 6, 2026 [1]. - The lawsuit claims that monday.com misrepresented its growth prospects, particularly regarding new customer growth and enterprise sales cycles, which undermined its $1.8 billion revenue target for 2027 [1]. - Following a disclosure on February 9, 2026, that the company would no longer discuss its 2027 targets, monday.com's stock price fell nearly 21% [1]. Group 2: Allegations Against Executives - The lawsuit alleges that the executives created a false impression of reliable information regarding the company's projected revenue and growth [1]. - It is claimed that the executives failed to disclose critical information about decelerating customer growth and longer sales cycles, which affected investor confidence [1]. - The misleading statements provided by the executives did not account for the actual performance variables impacting the company's growth [1]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows investors who suffered losses during the class period to seek appointment as lead plaintiff in the lawsuit [1]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is noted for its significant recoveries in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [1].

Core Points - A class action lawsuit has been filed against CoreWeave, Inc. on behalf of investors who acquired its securities between March 28, 2025, and December 15, 2025 [1] - CoreWeave is an AI cloud computing company based in Livingston, NJ, offering advanced AI infrastructure and proprietary software through its Cloud Platform [2] - The company's IPO on March 28, 2025, priced shares at $40, which surged to $183.58 by June 20, 2025, indicating strong demand [3] - The lawsuit alleges that CoreWeave made misstatements regarding its ability to meet demand and downplayed risks associated with reliance on a single third-party data center provider [3] - Significant losses were reported by investors when the truth about the company's operations began to emerge in October 2025 [3]